lidocaine; tetracaine - Profile

What are the generic sources for lidocaine; tetracaine and what is the scope of freedom to operate?

Lidocaine; tetracaine is the generic ingredient in two branded drugs marketed by Crescita Therap and Galen Specialty, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lidocaine; tetracaine has seven patent family members in seven countries.

Summary for lidocaine; tetracaine

International Patents:	7
US Patents:	3
Tradenames:	2
Applicants:	2
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lidocaine; tetracaine

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for lidocaine; tetracaine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006		RX	Yes	Yes			Y
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006		RX	Yes	Yes			Y
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006		RX	Yes	Yes			Y
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005		DISCN	Yes	No

Expired US Patents for lidocaine; tetracaine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005
Galen Specialty	SYNERA	lidocaine; tetracaine	PATCH;TOPICAL	021623-001	Jun 23, 2005

International Patents for lidocaine; tetracaine

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011088333
Australia	2011205730	Solid-forming local anesthetic formulations for pain control
European Patent Office	2523660	FORMULATIONS POUR ANESTHÉSIE LOCALE SE SOLIDIFIANT POUR LA GESTION DE LA DOULEUR (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL)
Mexico	2012008168	FORMULACIONES ANESTESICAS LOCALES QUE FORMAN SOLIDOS PARA CONTROL DEL DOLOR. (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL.)
Brazil	112012017554	formulações de anestésicas locais formadoras de sólido para controle da dor
China	102834096	Solid-forming local anesthetic formulations for pain control

Investment Scenario, Market Dynamics, and Financial Trajectory of Lidocaine and Tetracaine

Last updated: February 3, 2026

Summary

Lidocaine and tetracaine are longstanding local anesthetics with diverse applications in medical and dental procedures. Their market stability, evolving landscape, and patent status significantly influence investment opportunities. Current dynamics indicate steady demand driven by a growing healthcare sector, clinical innovations, and regulatory pathways for formulations. The combined market size for lidocaine and tetracaine was valued at approximately USD 2.4 billion globally in 2022, with projections reaching USD 3.2 billion by 2030, growing at a CAGR of 4.2%. This review analyzes market drivers, competitive landscape, regulatory environment, and financial outlook, providing insights for stakeholders seeking strategic positioning.

---

What Is the Current Market Size and Growth Trajectory?

Parameter	2022	2025 (Projected)	2030 (Projected)
Global Market Value (USD)	~2.4 B	~2.9 B	~3.2 B
CAGR	N/A	4.0% – 4.5%	4.2%

Source: Market Research Future (2022), Grand View Research (2023).

Market Breakdown:

• Lidocaine: Dominates the local anesthetic market (approx. 60% of the total), driven by dental, dermatological, and surgical applications.
• Tetracaine: Niche but vital in ophthalmology, spinal anesthetics, and topical formulations.

---

What Are the Key Market Drivers?

Drivers	Details
Growing Healthcare Infrastructure	Expansion in outpatient and surgical centers worldwide escalates demand.
Aging Population	Increased procedures in geriatric populations fuel anesthetic needs.
Advances in Delivery Systems	Development of sustained-release, topical, and patch formulations enhances therapeutic options.
Regulatory Approvals & Innovations	Approval of new indications and combination formulations expand target markets.
COVID-19 Pandemic	Surge in procedures, especially in dental and dermatology, temporarily boosted demand.

---

What Are the Market Challenges and Risks?

Challenges	Impacts
Generic Competition & Patent Expiries	Reduced pricing power post-patent expiry (Lidocaine patents expired in early 2000s).
Regulatory Hurdles	Approvals for novel delivery methods require extensive trials.
Pricing Pressure & Reimbursement Policies	Health authorities' cost containment measures influence profit margins.
Alternate Local Anesthetics & New Technologies	Emergence of liposomal and nanoparticle formulations pose competition.

---

What Is the Patent and Regulatory Landscape?

Drug/Formulation	Patent Status/Expiration	Key Regulatory Paths
Lidocaine	Patent expired (~2005); multiple formulations now off-patent	FDA, EMA approval for various formulations, biosimilars under development
Tetracaine	Patent expired (~2010); newer formulations seeking approval	FDA, EMA, with interest in novel delivery systems

Implication:

The expiration of patents indicates high generic competition but also opportunities for development of differentiation through delivery innovations and combination formulations.

---

What Are the Investment Opportunities?

1. Generic Manufacturing & Market Share Expansion

• Existing manufacturers can achieve cost efficiencies.
• Entry strategies into emerging markets with high procedural volumes.

2. Development of Novel Formulations

• Liposomal, transdermal patches, and sustained-release systems.
• Combining lidocaine/tetracaine with adjuncts for enhanced efficacy.

3. Biosimilars & Biobetters

• Increasing focus on biosimilars; licensing opportunities.

4. Therapeutic Innovations & New Indications

• Investigate non-traditional pain management applications.
• Regulatory pathways for new indications could unlock value.

---

How Do Competitors and Market Players Compare?

Major Companies	Market Share	Key Strategies	Innovations
Hospira (Pfizer)	~20%	Focus on generic expansions	Biosimilars and new formulations
Teva Pharmaceuticals	~15%	Cost leadership and broad portfolio	Transdermal patches
Mylan (now part of Viatris)	~10%	Market penetration in emerging economies	Combination products
Others	~55%	Niche and regional players	R&D into novel delivery systems

---

What Are the Regulatory and Policy Trends?

Trend	Impact
Streamlined FDA Approval for Generics	Accelerates market entry post-patent expiry
Orphan Drug Designations	Limited for current uses but potentially for niche indications
Pricing & Reimbursement Policies	Vary across regions, influencing margins

Policy Focus:

• The US FDA’s “Drug Competition Action Plan” (2020) promotes biosimilars and generics.
• European Directorate for the Quality of Medicines (EDQM) offers centralized procedures favoring market access.

---

Financial Projections & Key Metrics

Indicator	2022	2025	2030
Market Revenue (USD)	2.4 billion	2.9 billion	3.2 billion
Number of Major Formulations	50+	65+	80+
Average Price per Dose (USD)	$0.50–$2.00	Stable/slightly declining	Decline expected due to generic competition
R&D Investment (USD)	Variable	Focus on formulations	Significant if innovative devices targeted

---

How Is the Competitive Landscape Evolving?

Emerging Trends	Implications for Investors
Increased R&D in Delivery Systems	Potential for premium-priced formulations
Consolidation & Partnerships	Larger players acquiring smaller innovators or biosimilar producers
Geographic Expansion	Entry into markets with rising procedural volumes (China, India, Africa)
Digital & Personalized Medicine	Use of digital tools for better delivery and patient adherence

---

Key Takeaways

• Market Stability & Growth: The lidocaine and tetracaine market exhibits moderate but stable growth, driven by procedural volume increases and technological innovation.
• Patent Lifecycle & Competition: The expiration of primary patents offers opportunities for generics but pressures pricing; innovation in delivery systems can sustain margins.
• Investment Opportunities: Range from generic manufacturing, formulation innovation, to development of biosimilars and combination products.
• Regulatory Environment: Favorable pathways exist for generics, but novel formulations face rigorous approval processes.
• Market Risks: Price erosion, competitive entry, and regulatory hurdles require vigilant risk management.

Conclusion:
Investors should consider diversified strategies emphasizing formulation innovation, geographic expansion, and partnerships aligned with regulatory trends to capitalize on the evolving lidocaine and tetracaine markets.

---

Frequently Asked Questions

1. What are the primary applications driving demand for lidocaine and tetracaine?

Lidocaine primarily supports dental anesthesia, dermatological procedures, and minor surgeries. Tetracaine is favored for ocular anesthesia, spinal blocks, and topical skin applications.

2. How does patent expiration affect the market?

Patent expirations have increased generic supply, reducing prices and margins for brand-name producers but opening opportunities for cost-effective formulations and new delivery systems.

3. What innovation trends are shaping future growth?

Development of liposomal, transdermal patches, sustained-release formulations, and combination products are key trends offering higher margins and new indications.

4. Which geographic markets offer the highest growth potential?

Emerging markets in Asia, Africa, and Latin America show robust procedural growth, with increasing healthcare infrastructure supporting higher anesthetic volumes.

5. How do regulatory policies influence market entry and competition?

Streamlined approval processes for generics facilitate rapid market entry post-patent expiry, but novel formulations require extensive clinical data and regulatory engagement.

---

References

1. Market Research Future, "Global Local Anesthetics Market Analysis," 2022.
2. Grand View Research, "Pharmaceuticals - Local Anesthetics Industry Trends," 2023.
3. US Food and Drug Administration (FDA), "Regulatory Pathways for Generic Drugs," 2022.
4. European Directorate for the Quality of Medicines (EDQM), "Market Access and Policy Updates," 2023.